Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Interleukin 11

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Interleukin 11. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-019952-35 Sponsor Protocol Number: CS001P3 Start Date*: 2010-09-14
    Sponsor Name:CEL-SCI Corporation
    Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad...
    Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001188-22 Sponsor Protocol Number: MIMMA Start Date*: 2013-09-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant
    Medical condition: Multiple Myeloma patients underwent to autologous bone marrow transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003858-33 Sponsor Protocol Number: AM0010-301 Start Date*: 2017-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi...
    Medical condition: Advanced Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020065-24 Sponsor Protocol Number: WA25204 Start Date*: 2011-08-15
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LV (Completed) BE (Completed) AT (Completed) LT (Completed) CZ (Completed) DE (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001571-32 Sponsor Protocol Number: APHP200406 Start Date*: 2020-04-15
    Sponsor Name:Assistance Publique Hôpitaux de Paris
    Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004141-32 Sponsor Protocol Number: M19-977 Start Date*: 2020-09-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to S...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA PL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003444-30 Sponsor Protocol Number: C0743T12 Start Date*: 2007-05-15
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005154-57 Sponsor Protocol Number: CACZ885D2307E1 Start Date*: 2012-01-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom...
    Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001540-56 Sponsor Protocol Number: 208657 Start Date*: 2019-08-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023562-51 Sponsor Protocol Number: BT-CL-PGG-CRC1031 Start Date*: 2011-11-17
    Sponsor Name:Biothera
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005406-54 Sponsor Protocol Number: M14TIL Start Date*: 2014-05-09
    Sponsor Name:Antoni van Leeuwenhoek ziekenhuis
    Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab...
    Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003497-48 Sponsor Protocol Number: EMPATHY Start Date*: 2021-11-29
    Sponsor Name:Medical University of Warsaw
    Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004252-37 Sponsor Protocol Number: IPH1101-204 Start Date*: 2007-10-11
    Sponsor Name:Innate Pharma
    Full Title: A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018585-23 Sponsor Protocol Number: A4061051 Start Date*: 2010-12-21
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017
    Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003614-13 Sponsor Protocol Number: hzVSF_v13-0006 Start Date*: 2020-12-18
    Sponsor Name:ImmuneMed Inc.
    Full Title: Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-control...
    Medical condition: Moderate-to-severe COVID-19 pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001389-10 Sponsor Protocol Number: IASO Start Date*: 2017-09-28
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust & University of Cambridge
    Full Title: A phase II randomised placebo controlled double blinded trial of Interleukin 1 blockade in Acute Severe Colitis
    Medical condition: Acute Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016670 10066678 Acute ulcerative colitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-001152-29 Sponsor Protocol Number: 201956 Start Date*: 2015-07-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) CZ (Completed) EE (Completed) SK (Completed) GR (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003229-12 Sponsor Protocol Number: M19-944 Start Date*: 2020-01-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003050-23 Sponsor Protocol Number: VTX002-201 Start Date*: 2021-10-25
    Sponsor Name:Oppilan Pharma Ltd., wholy owned subsidiary of Ventyx Biosciences Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcer...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) FR (Completed) BG (Trial now transitioned) SK (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 14:08:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA